Advances in biomarker development are revolutionizing the way we study, diagnose and treat disease. However, progress in the development and use of biomarkers for diseases of the central nervous system has been limited by a number of difficulties -- including the inherent barriers associated with studying the brain. Development of reliable biomarkers for brain disorders would dramatically accelerate research on the etiology, pathophysiology, disease progression, and therapeutic development of many very prevalent and devastating diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and others. International experts in the field have contributed chapters to this volume that discuss the latest advances in biomarker technologies and biomarker development for brain disorders, as well as the logistical, regulatory and funding challenges experienced by scientists working on clinical trials for biomarkers NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.